中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 4
Apr.  2024
Turn off MathJax
Article Contents

Recommendations from Annals of Surgical Oncology: Clinical guidelines for extrahepatic cholangiocarcinoma and gallbladder carcinoma

DOI: 10.12449/JCH240407
Research funding:

National Natural Science Foundation of China (81972726);

Natural Science Foundation of Shanghai (22ZR1477900);

Henan Provincial Medical Science and Technology Research Project (LHGJ20190512)

More Information
  • Corresponding author: YANG Tian, yangtian6666@hotmail.com (ORCID: 0000-0003-1544-0976)
  • Received Date: 2024-03-02
  • Accepted Date: 2024-03-10
  • Published Date: 2024-04-11
  • Biliary tract carcinoma (BTC) is a type of gastrointestinal tumor with a low incidence rate and a strong invasive ability, mainly including intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder carcinoma (GC), often accompanied by local progression or distant metastasis. Surgery is often the preferred treatment method for patients with local resectable tumor; however, there is still a high risk of recurrence after radical surgery. Therefore, multiple treatment modalities are often required for BTC patients, including surgical resection, systemic treatment (such as targeted therapy, chemotherapy, and immunotherapy), and/or a combination of local treatment methods. With the development of the field of BTC, it is critical for surgical oncologists to understand and master the latest surgical strategies and the best patient selection and management systems. In view of the complexity of treatment and the continuous development of diagnosis and treatment techniques, Annals of Surgical Oncology, an authoritative American journal of cancer surgery, recently published the practical diagnosis and treatment guidelines for hepatobiliary tumors, including hepatocellular carcinoma (HCC), ICC, ECC, and GC, aiming to provide more evidence-based evidence for the clinical management and decision-making of patients with hepatobiliary tumors. Due to the limitations of length and different emphases, this article mainly introduces the recommendations for the evaluation points and clinical treatment of ECC and GC in the guidelines, so as to provide a reference for clinical practice.

     

  • loading
  • [1]
    ONG AML. Outrunning burnout in a GI fellowship program during the COVID-19 pandemic[J]. Dig Dis Sci, 2020, 65( 8): 2161- 2163. DOI: 10.1007/s10620-020-06401-4.
    [2]
    KUDO M. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr, 2022, 11( 4): 592- 596. DOI: 10.21037/hbsn-22-143.
    [3]
    LEE AJ, CHUN YS. Intrahepatic cholangiocarcinoma: The AJCC/UICC 8th edition updates[J]. Chin Clin Oncol, 2018, 7( 5): 52. DOI: 10.21037/cco.2018.07.03.
    [4]
    CARDINALE V, SEMERARO R, TORRICE A, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors[J]. World J Gastrointest Oncol, 2010, 2( 11): 407- 416. DOI: 10.4251/wjgo.v2.i11.407.
    [5]
    WRONKA KM, GRĄT M, STYPUŁKOWSKI J, et al. Relevance of preoperative hyperbilirubinemia in patients undergoing hepatobiliary resection for hilar cholangiocarcinoma[J]. J Clin Med, 2019, 8( 4): 458. DOI: 10.3390/jcm8040458.
    [6]
    VOGEL A, BRIDGEWATER J, EDELINE J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34( 2): 127- 140. DOI: 10.1016/j.annonc.2022.10.506.
    [7]
    KELLEY RK, UENO M, YOO C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer(KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401( 10391): 1853- 1865. DOI: 10.1016/S0140-6736(23)00727-4.
    [8]
    DUMONCEAU JM, TRINGALI A, PAPANIKOLAOU IS, et al. Endoscopic biliary stenting: Indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy(ESGE) Clinical Guideline-Updated October 2017[J]. Endoscopy, 2018, 50( 9): 910- 930. DOI: 10.1055/a-0659-9864.
    [9]
    MANSOUR JC, ALOIA TA, CRANE CH, et al. Hilar cholangiocarcinoma: Expert consensus statement[J]. HPB, 2015, 17( 8): 691- 699. DOI: 10.1111/hpb.12450.
    [10]
    UEMURA K, MURAKAMI Y, SATOI S, et al. Impact of preoperative biliary drainage on long-term survival in resected pancreatic ductal adenocarcinoma: A multicenter observational study[J]. Ann Surg Oncol, 2015, 22( Suppl 3): S1238- S1246. DOI: 10.1245/s10434-015-4618-9.
    [11]
    STROM TJ, KLAPMAN JB, SPRINGETT GM, et al. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage[J]. Surg Endosc, 2015, 29( 11): 3273- 3281. DOI: 10.1007/s00464-015-4075-3.
    [12]
    MIURA F, SANO K, WADA K, et al. Prognostic impact of type of preoperative biliary drainage in patients with distal cholangiocarcinoma[J]. Am J Surg, 2017, 214( 2): 256- 261. DOI: 10.1016/j.amjsurg.2017.01.010.
    [13]
    TIEU AH, KUMBHARI V, JAKHETE N, et al. Diagnostic and therapeutic utility of SpyGlass(®) peroral cholangioscopy in intraductal biliary disease: Single-center, retrospective, cohort study[J]. Dig Endosc, 2015, 27( 4): 479- 485. DOI: 10.1111/den.12405.
    [14]
    PEREIRA P, VILAS-BOAS F, PEIXOTO A, et al. How SpyGlass™ may impact endoscopic retrograde cholangiopancreatography practice and patient management[J]. GE Port J Gastroenterol, 2018, 25( 3): 132- 137. DOI: 10.1159/000481859.
    [15]
    GÓMEZ-ESPAÑA MA, MONTES AF, GARCIA-CARBONERO R, et al. SEOM clinical guidelines for pancreatic and biliary tract cancer(2020)[J]. Clin Transl Oncol, 2021, 23( 5): 988- 1000. DOI: 10.1007/s12094-021-02573-1.
    [16]
    GOERE D, WAGHOLIKAR GD, PESSAUX P, et al. Utility of staging laparoscopy in subsets of biliary cancers: Laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma[J]. Surg Endosc, 2006, 20( 5): 721- 725. DOI: 10.1007/s00464-005-0583-x.
    [17]
    PRIMROSE JN, FOX RP, PALMER DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): A randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20( 5): 663- 673. DOI: 10.1016/S1470-2045(18)30915-X.
    [18]
    BANALES JM, MARIN JJG, LAMARCA A, et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17( 9): 557- 588. DOI: 10.1038/s41575-020-0310-z.
    [19]
    SOARES KC, KAMEL I, COSGROVE DP, et al. Hilar cholangiocarcinoma: Diagnosis, treatment options, and management[J]. Hepatobiliary Surg Nutr, 2014, 3( 1): 18- 34. DOI: 10.3978/j.issn.2304-3881.2014.02.05.
    [20]
    BHUTIANI N, SCOGGINS CR, MCMASTERS KM, et al. The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: A multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. Surgery, 2018, 163( 4): 726- 731. DOI: 10.1016/j.surg.2017.10.028.
    [21]
    WAHAB MA, SULTAN AM, SALAH T, et al. Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: Is it of value?[J]. Hepato-gastroenterology, 2012, 59( 114): 321- 324. DOI: 10.5754/hge11999.
    [22]
    WEBER SM, RIBERO D, O’REILLY EM, et al. Intrahepatic cholangiocarcinoma: Expert consensus statement[J]. HPB, 2015, 17( 8): 669- 680. DOI: 10.1111/hpb.12441.
    [23]
    HEIMBACH JK, GORES GJ, HADDOCK MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Semin Liver Dis, 2004, 24( 2): 201- 207. DOI: 10.1055/s-2004-828896.
    [24]
    BREUER E, MUELLER M, DOYLE MB, et al. Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study[J]. Ann Surg, 2022, 276( 5): 846- 853. DOI: 10.1097/SLA.0000000000005641.
    [25]
    ETHUN CG, LOPEZ-AGUIAR AG, ANDERSON DJ, et al. Transplantation versus resection for hilar cholangiocarcinoma: An argument for shifting treatment paradigms for resectable disease[J]. Ann Surg, 2018, 267( 5): 797- 805. DOI: 10.1097/SLA.0000000000002574.
    [26]
    PARK JH, CHOI EK, AHN SD, et al. Postoperative chemoradiotherapy for extrahepatic bile duct cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 79( 3): 696- 704. DOI: 10.1016/j.ijrobp.2009.12.031.
    [27]
    BORGHERO Y, CRANE CH, SZKLARUK J, et al. Extrahepatic bile duct adenocarcinoma: Patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone[J]. Ann Surg Oncol, 2008, 15( 11): 3147- 3156. DOI: 10.1245/s10434-008-9998-7.
    [28]
    KIM TH, HAN SS, PARK SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81( 5): e853- e859. DOI: 10.1016/j.ijrobp.2010.12.019.
    [29]
    LIM KH, OH DY, CHIE EK, et al. Adjuvant concurrent chemoradiation therapy(CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer: A non-randomized, single center study[J]. BMC Cancer, 2009, 9: 345. DOI: 10.1186/1471-2407-9-345.
    [30]
    NELSON JW, GHAFOORI AP, WILLETT CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2009, 73( 1): 148- 153. DOI: 10.1016/j.ijrobp.2008.07.008.
    [31]
    HUGHES MA, FRASSICA DA, YEO CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct[J]. Int J Radiat Oncol Biol Phys, 2007, 68( 1): 178- 182. DOI: 10.1016/j.ijrobp.2006.11.048.
    [32]
    BEN-JOSEF E, GUTHRIE KA, EL-KHOUEIRY AB, et al. SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015, 33( 24): 2617- 2622. DOI: 10.1200/JCO.2014.60.2219.
    [33]
    HAWKINS WG, DEMATTEO RP, JARNAGIN WR, et al. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer[J]. Ann Surg Oncol, 2004, 11( 3): 310- 315. DOI: 10.1245/aso.2004.03.011.
    [34]
    DASARI BVM, IONESCU MI, PAWLIK TM, et al. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: A systematic review and meta-analysis[J]. J Surg Oncol, 2018, 118( 3): 477- 485. DOI: 10.1002/jso.25186.
    [35]
    NISHIO H, EBATA T, YOKOYAMA Y, et al. Gallbladder cancer involving the extrahepatic bile duct is worthy of resection[J]. Ann Surg, 2011, 253( 5): 953- 960. DOI: 10.1097/SLA.0b013e318216f5f3.
    [36]
    REGIMBEAU JM, FUKS D, BACHELLIER P, et al. Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group[J]. Eur J Surg Oncol, 2011, 37( 6): 505- 512. DOI: 10.1016/j.ejso.2011.03.135.
    [37]
    ALOIA TA, JÁRUFE N, JAVLE M, et al. Gallbladder cancer: Expert consensus statement[J]. HPB, 2015, 17( 8): 681- 690. DOI: 10.1111/hpb.12444.
    [38]
    FUKS D, REGIMBEAU JM, LE TREUT YP, et al. Incidental gallbladder cancer by the AFC-GBC-2009 Study Group[J]. World J Surg, 2011, 35( 8): 1887- 1897. DOI: 10.1007/s00268-011-1134-3.
    [39]
    LEE SE, JANG JY, LIM CS, et al. Systematic review on the surgical treatment for T1 gallbladder cancer[J]. World J Gastroenterol, 2011, 17( 2): 174- 180. DOI: 10.3748/wjg.v17.i2.174.
    [40]
    QADAN M, KINGHAM TP. Technical aspects of gallbladder cancer surgery[J]. Surg Clin North Am, 2016, 96( 2): 229- 245. DOI: 10.1016/j.suc.2015.12.007.
    [41]
    RUFF SM, CLOYD JM, PAWLIK TM. Annals of surgical oncology practice guidelines series: Management of primary liver and biliary tract cancers[J]. Ann Surg Oncol, 2023, 30( 13): 7935- 7949. DOI: 10.1245/s10434-023-14255-z.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Article Metrics

    Article views (244) PDF downloads(91) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return